Explore by Category

ASH 2021: Meet Valarie Traynham - Personalized Medicine for a Personal Disease

MYELOMA NEWS - December 04, 2021

Fostering community and change are essential parts of Valarie Traynham’s DNA.  After her diagnosis she started attending a local support group and so... Read More

ASH 2021: Myeloma Crowd by HealthTree Has ASH Covered

MYELOMA NEWS - December 03, 2021

The annual American Society of Hematology (ASH) meeting is the most important important meeting of the year for medical professionals working in myeloma.  ... Read More

Darzalex FASPRO Gets FDA Approval for Use With Carfilzomib and Dexamethasone

MYELOMA NEWS - December 01, 2021

Darzalex FASPRO (the subcutaneous shot of daratumumab) has received its ninth FDA approval, this time with use in combination with carfilzomib and dexamethasone... Read More

A Potential Warning Sign for Allo CAR T in Multiple Myeloma

MYELOMA NEWS - November 24, 2021

Myeloma Crowd by HealthTree has posted several articles recently here and here about the potential of donor CAR-T cell therapy. These CAR-T cells have the ... Read More

Dual Myeloma CAR T Targeting BCMA and CD19 Gets FDA Orphan Drug Designation

MYELOMA NEWS - November 23, 2021

  China-based Gracell Biotechnologies was recently given FDA Orphan Drug designation for a dual CAR T targeting BCMA and CD19 in multiple myelom... Read More

New Genetic Subdivisions Help Separate Myeloma Risk and Potentially Personalize Treatments

MYELOMA NEWS - November 19, 2021

Mount Sinai researchers have identified new ways of classifying myeloma sub-types to define risk in a paper published in Science Advances.  The new tool, c... Read More

FDA Extends Janssen's Cilta-Cel PDUFA Date

MYELOMA NEWS - November 02, 2021

Janssen announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) date for the CAR T therapy, cilta-cel) Biologics License Application. The... Read More

The Man Who Changed Cancer Forever: Meet Jim Allison, November 15th @ 3 PM Eastern

MYELOMA NEWS - October 29, 2021

“Wondrous."  That’s how Nobel Prize-winning immunotherapy pioneer Jim Allison sums up the promise of immunotherapy to help the human immun... Read More

Why Oncopeptides Withdrew its FDA Application for Melflufen (PEPAXTO) in Multiple Myeloma

MYELOMA NEWS - October 27, 2021

Oncopeptides AB has decided to withdraw their US FDA application for melflufen, but will continue to support myeloma patients currently on the drug.  ... Read More

A New Type of CAR Multiple Myeloma Therapy: CAR NK Cells

MYELOMA NEWS - October 21, 2021

  Researchers in Spain believe that a new type of CAR therapy using natural killer cells, could be more effective and have fewer side effects in treat... Read More

Join Nobel Prize Winner and Immunotherapy Pioneer Dr. Jim Allison on November 15th @ 3 PM Eastern

MYELOMA NEWS - October 15, 2021

On November 15th, 2021 at 3 PM Eastern we will have the unique opportunity to hear from Nobel Prize Winner and Immunotherapy Pioneer, Dr. Jim Allison, and his w... Read More

Myeloma Patient Responses to the COVID Vaccine with Dr. Parekh and Dr. Van Oekelen, Oct 27 @ 3pm Eastern

MYELOMA NEWS - October 12, 2021

The Myeloma Crowd Community program is pleased to welcome Drs. Samir Parekh and Oliver Van Oekelen ashare findings from their studies about how myelom... Read More

IMW: Iberdomide Demonstrates Ability to Overcome Resistance to Common Myeloma Therapies

MYELOMA NEWS - October 07, 2021

A new drug called iberdomide when combined with daratumumab, bortezomib or carfilzomib is showing positive effects with fewer side effects than its predecessor ... Read More

Thanks to our Myeloma Crowd Community sponsors:

.                         .       .